CO44194

Topic of Study: Breast Cancer

Sponsor: Genentech, Inc.

Principal Investigator: David A. Riseberg, M.D., 410-783-5858

Research Coordinator: Alexandra Cline, RN, 410-951-7956; Shannon Householder, RN, 410-951-7908; Sarah Orndorff, RN 410-332-9459

Coordinated Through: Institutional Research

This is a study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in participants with previously untreated, PD-L1-Positive, locally-advanced unresectable or metastatic Triple-Negative breast cancer. (Clinicaltrials.gov ID#: NCT05852691)